Skip to content
10-Q

Quarterly Report

SORRENTO THERAPEUTICS, INC.

0000950170-23-022152

← back to feed
Filed
May 15, 2023 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2023 · May 8, 2023 551.28M sh
Shares Diluted Q1 2023 · Mar 31, 2023 543.14M sh
Shares Diluted Q1 2023 · Mar 31, 2022 337.12M sh
Capex Q1 2023 · Mar 31, 2023 $86K
Capex Q1 2023 · Mar 31, 2022 $2.59M
Operating Cash Flow Q1 2023 · Mar 31, 2023 −$49.46M
Operating Cash Flow Q1 2023 · Mar 31, 2022 −$83.36M
Long Term Debt Q1 2023 · Mar 31, 2023 $21.4M
Long Term Debt Q1 2023 · Dec 31, 2022 $19.13M
Short Term Debt Q1 2023 · Mar 31, 2023 $49.64M
Short Term Debt Q1 2023 · Dec 31, 2022 $16.29M
Cash And Equivalents Q1 2023 · Mar 31, 2023 $37.66M
Cash And Equivalents Q1 2023 · Dec 31, 2022 $23.63M
Cash And Equivalents Q1 2023 · Mar 31, 2022 $111.91M
Stockholders Equity Q1 2023 · Mar 31, 2023 −$125.5M
Stockholders Equity Q1 2023 · Dec 31, 2022 −$18.61M
Current Liabilities Q1 2023 · Mar 31, 2023 $165.63M
Current Liabilities Q1 2023 · Dec 31, 2022 $327.92M
Total Liabilities Q1 2023 · Mar 31, 2023 $587.48M
Total Liabilities Q1 2023 · Dec 31, 2022 $494.51M
Current Assets Q1 2023 · Mar 31, 2023 $100.76M
Current Assets Q1 2023 · Dec 31, 2022 $96.37M
Total Assets Q1 2023 · Mar 31, 2023 $460.06M
Total Assets Q1 2023 · Dec 31, 2022 $472.84M
Eps Diluted Q1 2023 · Mar 31, 2023 −$0.26
Eps Diluted Q1 2023 · Mar 31, 2022 −$0.12
Eps Basic Q1 2023 · Mar 31, 2023 −$0.26
Eps Basic Q1 2023 · Mar 31, 2022 −$0.12
Net Income Q1 2023 · Mar 31, 2023 −$139.62M
Net Income Q1 2023 · Mar 31, 2022 −$40.82M
Operating Income Q1 2023 · Mar 31, 2023 −$106.34M
Operating Income Q1 2023 · Mar 31, 2022 −$106.88M